Endocyte Inc (ECYT) 2.98 $ECYT Endocyte to Present at

New Post Public Reply Private Reply Replies (0) Message Board

Sep 19, 2016 at 9:03 AM

Endocyte Inc (ECYT) 2.98 $ECYT

Endocyte to Present at the 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Tue Aug 09, 3:01PM CDT
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, Aug. 16, at 12:45 p.m. EDT. The conference will be held at the Le Parker Meridien Hotel in New York.
ECYT: 2.98 (-0.04)

Endocyte (ECYT) Q2 Loss Wider than Expected (Revised)
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 4:31AM CDT
Endocyte (ECYT) reported a second-quarter 2016 loss of 33 cents per share, wider than the Zacks Consensus Estimate of a loss of 26 cents.
ECYT: 2.98 (-0.04), GERN: 1.99 (+0.11), LGND: 115.54 (+0.46), CORT: 5.76 (+0.01)

Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:55AM CDT
Endocyte (ECYT) reported a second-quarter 2016 loss of 25 cents per share, narrower than the Zacks Consensus Estimate of a loss of 26 cents.
ECYT: 2.98 (-0.04), GERN: 1.99 (+0.11), CORT: 5.76 (+0.01), ANIK: 47.37 (unch)

Endocyte Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:01PM CDT
- Reached Maximum Tolerated Dose in Twice Weekly Dosing Schedule with EC1456 -
ECYT: 2.98 (-0.04)

Endocyte Announces Second Quarter 2016 Earnings Conference Call
GlobeNewswire - Thu Jul 28, 3:01PM CDT
Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Thursday, August 4th, at 4:30 p.m. EDT to discuss its second quarter financial results and provide an operational update.
ECYT: 2.98 (-0.04)

Whta's in Store for Endocyte (ECYT) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Endocyte, Inc. (ECYT) is expected to report second-quarter 2016 results on Aug 2.
IPXL: 26.15 (+0.27), ECYT: 2.98 (-0.04), IRWD: 14.92 (-0.13), EXEL: 13.69 (+0.14)

Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Thu May 26, 3:01PM CDT
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented on its lead, clinical-stage assets, EC1456 and EC1169, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 - 7, 2016, in Chicago.
ECYT: 2.98 (-0.04)

Endocyte (ECYT) Reports Narrower than Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Thu May 05, 3:01PM CDT
Endocyte, Inc. (ECYT) reported a first-quarter 2016 loss of 24 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 26 cents and the year-ago loss of 26 cents.
MNK: 76.12 (-0.15), ECYT: 2.98 (-0.04), SHPG: 198.26 (-2.34), NKTR: 19.08 (-0.17)

Endocyte (ECYT) Reports a Narrower Q1 Loss
Ekta Bagri - Zacks Investment Research - Wed May 04, 7:53AM CDT
Endocyte reported a loss per share of 24 cents per share while our consensus called for a loss of 26 cents per share
ECYT: 2.98 (-0.04)

Endocyte reports 1Q loss
Automated Insights - Wed May 04, 7:22AM CDT
WEST LAFAYETTE, Ind. (AP) _ Endocyte Inc. (ECYT) on Wednesday reported a loss of $10.9 million in its first quarter.
ECYT: 2.98 (-0.04)

Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More
Zacks Equity Research - Zacks Investment Research - Tue May 03, 8:08AM CDT
How will biotech stocks Regeneron, Ligand, Ionis and others fare in the first quarter of 2016?
RDUS: 56.39 (+1.27), ECYT: 2.98 (-0.04), CLDX: 3.65 (-0.05), LGND: 115.54 (+0.46), AMGN: 173.52 (+0.56), IONS: 32.21 (+0.46), REGN: 408.63 (+5.88)

Endocyte (ECYT): What Awaits the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:20AM CDT
Endocyte, Inc. (ECYT) is slated to report first-quarter 2016 results on May 4.
IPXL: 26.15 (+0.27), ECYT: 2.98 (-0.04), JAZZ: 126.04 (-1.77), XON: 28.33 (+0.48)

Endocyte Announces First Quarter 2016 Earnings Conference Call
GlobeNewswire - Wed Apr 27, 3:01PM CDT
Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, May 4th, at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update.
ECYT: 2.98 (-0.04)

Endocyte Announces Promising Preclinical Data for Application of SMDC Technology in CAR T Cell Therapy in Late-Breaking Abstract at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:01AM CDT
-- Poster demonstrates novel approach to a universal T cell overcoming key challenges of current chimeric antigen receptor (CAR) technologies/therapies
ECYT: 2.98 (-0.04)

Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Mon Apr 11, 3:01PM CDT
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that four posters will be presented by Endocyte scientists at the American Association for Cancer Research (AACR) Annual Meeting 2016 to be held in New Orleans, April 16-20, 2016.
ECYT: 2.98 (-0.04)

BUYINS.NET: SOXL, AMRC, GDOT, SCHC, ECYT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Feb 04, 6:31AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Direxion Daily Semiconductor Bull 3X Shares (NYSE:SOXL), Ameresco Inc (NYSE:AMRC), Green Dot Corp (NYSE:GDOT), Schwab US Large Cap Etf (NYSE:SCHC), ENDOCYTE INC (NASDAQ:ECYT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
AMRC: 5.05 (+0.10), ECYT: 2.98 (-0.04), GDOT: 22.83 (-0.26), SOXL: 42.72 (+0.02), SCHC: 30.00 (-0.22)

Valeant to Up Incentives to Retain Key Employees Amid Turmoil
Zacks Equity Research - Zacks Investment Research - Fri Nov 20, 11:50AM CST
Valeant Pharmaceuticals (VRX) is planning to offer cash and incentives to important employees in the U.S. to retain them amid the current turmoil.
ECYT: 2.98 (-0.04), VRX: 27.54 (+0.26), NVO: 46.44 (+0.32), LLY: 78.80 (-0.02)

Endocyte (ECYT) Shows Strength: Stock Moves Up 11.5%
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 7:15AM CST
Endocyte, Inc. (ECYT) shares rise over 11% in the last trading session.
ECYT: 2.98 (-0.04), CXRX: 5.40 (unch)

Endocyte (ECYT) Posts Narrower-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Wed Nov 04, 11:10AM CST
Endocyte's (ECYT) Q3 loss was narrower than expected.
ESPR: 11.22 (-0.02), ECYT: 2.98 (-0.04), MRK: 62.52 (+0.24), SPPI: 4.82 (-0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anderson University Sees Financial Turnaround Success

Anderson University, against all odds, is shaking up the financial narrative they’ve been stuck in for a while. It’s kind of like finding a $20 bill in an old coat—a nice surprise but it doesn’t happen every day. The university’s recent report on their financial progress is reminding folks that when it comes to fiscal discipline, sometimes you just need fresh...

Will Hair Loss Drugs Challenge Transplant Clinics?

Emerging Treatments Stir Up Hair Loss Scene You ever get the feeling we're on the brink of something big? That's where we are with hair loss treatments, folks. As of late 2026, new drugs are making waves in clinical trials, but they’re not yet giving hair transplant clinics any sleepless nights. Smile Hair Clinic's co-founders, Dr. Mehmet Erdo?an and Dr. Gökay Bilgin,...

Health In Tech's Rocky Q3: Navigating Losses and Opportunities

Signs of Optimism Amidst Financial Struggles Health In Tech is wading through the choppy waters of its Q3 2026 financial results—revenue came in at $6.6 million, down from $8.5 million the previous year. Seems like their investments are all geared up, but the sails aren’t quite catching wind yet. That said, their contracted revenue strutted to $32.7 million for the...

Goldwin Teams Up with Centric for PLM Overhaul

Solid Move or Risky Shift? Goldwin Inc., a well-regarded behemoth in Japan's outdoors market, is shaking things up and joining hands with Centric Software. We're looking at a modernization spree here, folks. The plan? Whip Goldwin's sprawling product data into shape with Centric PLM, a solution that promises a more structured product development approach. Streamlining,...

University of Phoenix Tackles Data: New Degree Insight

Giving Traditional Business Schools a Run for Their Money It's about time someone ditches that outdated case study method and starts teaching folks how to really harness data. Enter the University of Phoenix's new Bachelor of Science in Business Analytics. It's designed with working adults in mind. Wherever you are, this ain't your everyday degree program. It's an online...

The Melt Expands with Key Texas Franchise Deal

Throwing Down the Gauntlet: The Melt Expands If there's one thing I've learned after decades watching these restaurant chains multiply like rabbits it’s this: when a veteran gets involved, you perk up. The Melt has done just that by roping in Syed Ahmad—a name that actually means something in this game—to open eight new locations in the Lone Star State. It isn't...

ADI Global Faces Investor Investigation Over Major Write-Down

Towering Goodwill Falls and Investor Scrutiny Well, let's dig into this mess ADI Global Distribution has found itself in. If you were hanging onto ADIG shares, your portfolio probably took quite the hit when they revealed a nasty $659 million goodwill write-down. Imagine opening up those financials and seeing about 62% of goodwill value wiped out overnight. Suddenly, that...

U-wifi Gains Charlie Vogt: Key Steps in 5G Expansion

Charlie Vogt Joins U-wifi: A Broadband Game Changer? There's a new player in town shaking things up, and he's no rookie. Charlie Vogt, five-time technology CEO and Managing Director at Bowen, is hopping onto U-wifi's board of directors. This isn't just about another corporate announcement; it's like adding a veteran quarterback to your expansion team. Vogt’s pedigree in...

NueSynergy Secures Top Spot in HSA Provider Rankings

NueSynergy Earns its Stripes in 2026 It seems these days, healthcare costs are rising faster than you can say 'deductible.' In this chaotic landscape, a good HSA provider is worth its weight in gold. Enter NueSynergy, whose efforts have once again been acknowledged by Morningstar, a big name in the world of investment research. What Sets NueSynergy Apart? NueSynergy isn't...

Philip Scroggie's Legacy in Global Energy Projects

A Lifetime of Energy Industry Excellence When you've been around the block in the energy sector as long as Philip D. Scroggie has, you're bound to pick up a few accolades. Recognized as an Inner Circle Lifetime Member, this guy has etched his name in the annals of global energy project management. Yeah, he's been a heavyweight in the oil, gas, and LNG industries, and he's...